Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients.
Tamoxifen-induced DNA adducts were searched in leucocyte DNA from breast cancer patients. Total white blood cell DNA from tamoxifen-treated and control patients was analysed by 32P-postlabelling using HPLC-radioactivity detection. Rat liver DNA was used as a positive standard. In blinded analysis four of the six treated patients showed DNA adducts; none of the five controls were positive. The identity of fraction as a tamoxifen adduct was confirmed by using different chromatographic systems, each with spiked rat liver samples. The level of adducts in the treated patients was 5.5 adducts/10(9) nucleotides as compared to an apparent level of 1.9/10(9) in the controls.
Hemminki
K
K
Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden.
Rajaniemi
H
H
Koskinen
M
M
Hansson
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000032:analysis* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D018736:DNA Adducts / Q000032:analysis*; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000737:chemistry*; D008875:Middle Aged; D051381:Rats; D013629:Tamoxifen / Q000032:analysis* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D018736:DNA Adducts; D004273:DNA, Neoplasm; D013629:Tamoxifen